Hemophilia Treatment Market to Reach $26.9 Bn, Globally, by 2031 at 7.5% CAGR

Hemophilia treatment industry generated $12.8 billion in 2021, and is estimated to reach $26.9 billion by 2031, witnessing a CAGR of 7.5% from 2022 to 2031. Rise in the prevalence of hemophilia, technological advancements in hemophilia treatment, and supportive government initiatives for hemophilia management drive the growth of the global hemophilia treatment market. However, high cost of hemophilia treatments and adverse effects associated with plasma-derived products restrain the market growth. On the other hand, increase in R&D activities regarding treatment therapies, rise in the usage of prophylactic treatment, and surge in rate of diagnosis create new opportunities for the market growth in the coming years.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
• Bayer AG
• CSL Ltd. (CSL Behring)
• F. Hoffmann-La Roche AG
• Grifols, S.A
• Medexus Pharmaceuticals Inc.
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceuticals Company Ltd.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/301

𝗖𝗼𝘃𝗶𝗱-𝟭𝟵 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼:

• Owing to social distancing measures, possibility of cross contamination, and postponement of non-elective surgeries, the number of hemophilia treatments reduced considerably during the Covid-19 pandemic. This led to a negative impact on the global hemophilia treatment market.
• Manufacturers also suffered huge losses during the pandemic, due to decline in demand for hemophilia medicines for treatments. However, the market is expected to recover post-pandemic.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/301

Based on type, the hemophilia A segment accounted for the highest market share in 2021, contributing to more than four-fifths of the global hemophilia treatment market, and is estimated to maintain its lead status throughout the forecast period. Moreover, this segment is expected to manifest the fastest CAGR of 7.6% from 2022 to 2031. This is attributed to increase in incidence of hemophilia A, rise in use of factor VIII, and product approvals by the regulating authorities. The report also analyzes the hemophilia B segment.

Based on drug therapy, the recombinant coagulation factor concentrates therapy segment held the highest share in 2021, accounting for more than two-fifths of the global hemophilia treatment market, and is projected to maintain its leadership status by 2031. This is due to rise in the number of recombinant technology products available for the treatment. However, the non-factor replacement therapy segment is projected to witness the highest CAGR of 8.6% from 2022 to 2031, owing to increase in target population and rise in R&D activities for the treatment therapies.

Based on region, Europe contributed to the highest market share in terms of revenue in 2021, accounting for more than two-fifths of the global hemophilia treatment market, and is projected to continue its lead position by 2031. This is attributed to the well-established healthcare facilities, technological advancements, and surge in demand for early diagnosis of hemophilia. However, Asia-Pacific is estimated to witness the largest CAGR of 8.3% during the forecast period. This is due to surge in incidence of population suffering from hemophilia and rise in healthcare expenditure.

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

Enzymes Market -- https://www.alliedmarketresearch.com/enzymes-market

Pain Management Drugs Market --https://www.alliedmarketresearch.com/pain-management-therapeutics-market

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.